{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:24:13Z","timestamp":1786951453526,"version":"build-2736575974"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40263-026-01320-w","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:49:03Z","timestamp":1784656143000},"page":"1207-1223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sublingual Administration for Pain Control: Pharmacology, Clinical Applications and Future Directions"],"prefix":"10.1007","volume":"40","author":[{"given":"Sarang S.","family":"Koushik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Gritsenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanesh D.","family":"Binda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac S.","family":"Daybell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagun","family":"Raghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuella","family":"Borukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1060-429X","authenticated-orcid":false,"given":"Naum","family":"Shaparin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"20","key":"1320_CR1","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/s0024-3205(01)01550-8","volume":"70","author":"M Narita","year":"2002","unstructured":"Narita M, Imai S, Itou Y, Yajima Y, Suzuki T. Possible involvement of mu1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci. 2002;70(20):2341\u201354. https:\/\/doi.org\/10.1016\/s0024-3205(01)01550-8.","journal-title":"Life Sci"},{"issue":"3","key":"1320_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/clpt.1988.159","volume":"44","author":"DS Weinberg","year":"1988","unstructured":"Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988;44(3):335\u201342. https:\/\/doi.org\/10.1038\/clpt.1988.159.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1320_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40262-012-0016-7","volume":"52","author":"J L\u00f6tsch","year":"2013","unstructured":"L\u00f6tsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet. 2013;52(1):23\u201336. https:\/\/doi.org\/10.1007\/s40262-012-0016-7.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1320_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00044011-200828010-00001","volume":"28","author":"M Darwish","year":"2008","unstructured":"Darwish M, Kirby M, Jiang JG, Tracewell W, Robertson P. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects. Clin Drug Investig. 2008;28(1):1\u20137. https:\/\/doi.org\/10.2165\/00044011-200828010-00001.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1320_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1185\/03007995.2012.683111","volume":"28","author":"R Rauck","year":"2012","unstructured":"Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012;28(5):859\u201370. https:\/\/doi.org\/10.1185\/03007995.2012.683111.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1320_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/JCO.2016.69.9504","volume":"35","author":"E Zecca","year":"2017","unstructured":"Zecca E, Brunelli C, Centurioni F, Manzoni A, Pigni A, Caraceni A. Fentanyl sublingual tablets versus subcutaneous morphine for the management of severe cancer pain episodes in patients receiving opioid treatment: a double-blind, randomized, noninferiority trial. J Clin Oncol. 2017;35(7):759\u201365. https:\/\/doi.org\/10.1200\/JCO.2016.69.9504.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1320_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1089\/jpm.2006.0150","volume":"10","author":"GM Reisfield","year":"2007","unstructured":"Reisfield GM, Wilson GR. Rational use of sublingual opioids in palliative medicine. J Palliat Med. 2007;10(2):465\u201375. https:\/\/doi.org\/10.1089\/jpm.2006.0150.","journal-title":"J Palliat Med"},{"issue":"17","key":"1320_CR8","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.2165\/11200910-000000000-00000","volume":"70","author":"CM Chwieduk","year":"2010","unstructured":"Chwieduk CM, McKeage K. Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. Drugs. 2010;70(17):2281\u20138. https:\/\/doi.org\/10.2165\/11200910-000000000-00000.","journal-title":"Drugs"},{"issue":"6","key":"1320_CR9","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jpainsymman.2022.02.016","volume":"63","author":"V Guastella","year":"2022","unstructured":"Guastella V, Delorme J, Chenaf C, Authier N. The prevalence of off-label prescribing of transmucosal immediate-release fentanyl in France. J Pain Symptom Manag. 2022;63(6):980\u20137. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.02.016.","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"1320_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40261-015-0268-8","volume":"35","author":"L C\u00e1novas-Mart\u00ednez","year":"2015","unstructured":"C\u00e1novas-Mart\u00ednez L, Carceller-Ruiz JJ, D\u00edaz-Parada P, et al. Efficacy and safety of sublingual fentanyl tablets for the management of breakthrough pain in patients with chronic musculoskeletal pain with neuropathic component: multicenter prospective study. Clin Drug Investig. 2015;35(3):169\u201377. https:\/\/doi.org\/10.1007\/s40261-015-0268-8.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1320_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78002-0","volume":"10","author":"M Fihlman","year":"2020","unstructured":"Fihlman M, Karru E, Varpe P, et al. Feasibility of a transmucosal sublingual fentanyl tablet as a procedural pain treatment in colonoscopy patients: a prospective placebo-controlled randomized study. Sci Rep. 2020;10(1):20897. https:\/\/doi.org\/10.1038\/s41598-020-78002-0.","journal-title":"Sci Rep"},{"issue":"11","key":"1320_CR12","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1080\/03007995.2017.1371681","volume":"33","author":"RL Rauck","year":"2017","unstructured":"Rauck RL, Oh DA, Singla N, et al. Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a multiple ascending dose study in opioid-na\u00efve healthy volunteers. Curr Med Res Opin. 2017;33(11):1921\u201333. https:\/\/doi.org\/10.1080\/03007995.2017.1371681.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1320_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s13181-016-0535-y","volume":"12","author":"ACMT Position Statement","year":"2016","unstructured":"ACMT Position Statement. Safety issues regarding prescription fentanyl products. J Med Toxicol. 2016;12(2):211\u20132. https:\/\/doi.org\/10.1007\/s13181-016-0535-y.","journal-title":"J Med Toxicol"},{"issue":"7","key":"1320_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.2019.0235","volume":"321","author":"JE Rollman","year":"2019","unstructured":"Rollman JE, Heyward J, Olson L, Lurie P, Sharfstein J, Alexander GC. Assessment of the FDA risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products. JAMA. 2019;321(7):676\u201385. https:\/\/doi.org\/10.1001\/jama.2019.0235.","journal-title":"JAMA"},{"key":"1320_CR15","unstructured":"Research C for DE and. Transmucosal immediate-release fentanyl (TIRF) medicines. FDA. Published online September 19, 2024. https:\/\/www.fda.gov\/drugs\/information-drug-class\/transmucosal-immediate-release-fentanyl-tirf-medicines. Accessed 17 May 2026."},{"issue":"22","key":"1320_CR16","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1523\/JNEUROSCI.3723-08.2009","volume":"29","author":"MS Virk","year":"2009","unstructured":"Virk MS, Arttamangkul S, Birdsong WT, Williams JT. Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009;29(22):7341\u20138. https:\/\/doi.org\/10.1523\/JNEUROSCI.3723-08.2009.","journal-title":"J Neurosci"},{"issue":"6","key":"1320_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/bja\/aei145","volume":"94","author":"A Dahan","year":"2005","unstructured":"Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825\u201334. https:\/\/doi.org\/10.1093\/bja\/aei145.","journal-title":"Br J Anaesth"},{"issue":"5","key":"1320_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/bja\/ael051","volume":"96","author":"A Dahan","year":"2006","unstructured":"Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96(5):627\u201332. https:\/\/doi.org\/10.1093\/bja\/ael051.","journal-title":"Br J Anaesth"},{"issue":"7","key":"1320_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","volume":"44","author":"A Elkader","year":"2005","unstructured":"Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44(7):661\u201380. https:\/\/doi.org\/10.2165\/00003088-200544070-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1320_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/pm\/pnx321","volume":"20","author":"SCB Lim","year":"2019","unstructured":"Lim SCB, Schug S, Krishnarajah J. The pharmacokinetics and local tolerability of a novel sublingual formulation of buprenorphine. Pain Med. 2019;20(1):143\u201352. https:\/\/doi.org\/10.1093\/pm\/pnx321.","journal-title":"Pain Med"},{"issue":"7","key":"1320_CR21","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/pme.12386","volume":"15","author":"J Cote","year":"2014","unstructured":"Cote J, Montgomery L. Sublingual buprenorphine as an analgesic in chronic pain: a systematic review. Pain Med. 2014;15(7):1171\u20138. https:\/\/doi.org\/10.1111\/pme.12386.","journal-title":"Pain Med"},{"issue":"1","key":"1320_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/009127009703700106","volume":"37","author":"J Mendelson","year":"1997","unstructured":"Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37(1):31\u20137. https:\/\/doi.org\/10.1177\/009127009703700106.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1320_CR23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.4103\/joacp.joacp_245_23","volume":"40","author":"AS Nair","year":"2024","unstructured":"Nair AS, Dudhedia U, Bodas PV, Rangaiah M, Borkar N. Efficacy and safety of sublingual buprenorphine in managing acute postoperative pain - a systematic review. J Anaesthesiol Clin Pharmacol. 2024;40(4):574\u201381. https:\/\/doi.org\/10.4103\/joacp.joacp_245_23.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"5","key":"1320_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0885-3924(92)90061-l","volume":"7","author":"JA Grass","year":"1992","unstructured":"Grass JA. Sufentanil: clinical use as postoperative analgesic--epidural\/intrathecal route. J Pain Symptom Manag. 1992;7(5):271\u201386. https:\/\/doi.org\/10.1016\/0885-3924(92)90061-l.","journal-title":"J Pain Symptom Manag"},{"issue":"5","key":"1320_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/ALN.0000000000002145","volume":"128","author":"DM Fisher","year":"2018","unstructured":"Fisher DM, Chang P, Wada DR, Dahan A, Palmer PP. Pharmacokinetic properties of a sufentanil sublingual tablet intended to treat acute pain. Anesthesiology. 2018;128(5):943\u201352. https:\/\/doi.org\/10.1097\/ALN.0000000000002145.","journal-title":"Anesthesiology"},{"issue":"2","key":"1320_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/anae.14132","volume":"73","author":"T van de Donk","year":"2018","unstructured":"van de Donk T, Ward S, Langford R, Dahan A. Pharmacokinetics and pharmacodynamics of sublingual sufentanil for postoperative pain management. Anaesthesia. 2018;73(2):231\u20137. https:\/\/doi.org\/10.1111\/anae.14132.","journal-title":"Anaesthesia"},{"issue":"1","key":"1320_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.clinthera.2014.11.001","volume":"37","author":"SK Willsie","year":"2015","unstructured":"Willsie SK, Evashenk MA, Hamel LG, Hwang SS, Chiang YK, Palmer PP. Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. Clin Ther. 2015;37(1):145\u201355. https:\/\/doi.org\/10.1016\/j.clinthera.2014.11.001.","journal-title":"Clin Ther"},{"issue":"2","key":"1320_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1517\/17425255.2016.1134487","volume":"12","author":"R Babazade","year":"2016","unstructured":"Babazade R, Turan A. Pharmacokinetic and pharmacodynamic evaluation of sublingual sufentanil in the treatment of post-operative pain. Expert Opin Drug Metab Toxicol. 2016;12(2):217\u201324. https:\/\/doi.org\/10.1517\/17425255.2016.1134487.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"1320_CR29","first-page":"1411","volume":"20","author":"P Sacerdote","year":"2016","unstructured":"Sacerdote P, Coluzzi F, Fanelli A. Sublingual sufentanil, a new opportunity for the improvement of postoperative pain management in Italy. Eur Rev Med Pharmacol Sci. 2016;20(7):1411\u201322.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"1320_CR30","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-016-0571-6","volume":"76","author":"JE Frampton","year":"2016","unstructured":"Frampton JE. Sublingual sufentanil: a review in acute postoperative pain. Drugs. 2016;76(6):719\u201329. https:\/\/doi.org\/10.1007\/s40265-016-0571-6.","journal-title":"Drugs"},{"issue":"4","key":"1320_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40261-019-00772-x","volume":"39","author":"ED Deeks","year":"2019","unstructured":"Deeks ED. Sufentanil 30 \u00b5g sublingual tablet: a review in acute pain. Clin Drug Investig. 2019;39(4):411\u20138. https:\/\/doi.org\/10.1007\/s40261-019-00772-x.","journal-title":"Clin Drug Investig"},{"key":"1320_CR32","unstructured":"REMS Information for DSUVIA | Home. https:\/\/www.dsuviarems.com\/. Accessed 17 May 2026."},{"issue":"2","key":"1320_CR33","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/ALN.0000000000000746","volume":"123","author":"M Jove","year":"2015","unstructured":"Jove M, Griffin DW, Minkowitz HS, Ben-David B, Evashenk MA, Palmer PP. Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty: a randomized, placebo-controlled study. Anesthesiology. 2015;123(2):434\u201343. https:\/\/doi.org\/10.1097\/ALN.0000000000000746.","journal-title":"Anesthesiology"},{"issue":"2","key":"1320_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/03007995.2019.1681133","volume":"36","author":"E Pogatzki-Zahn","year":"2020","unstructured":"Pogatzki-Zahn E, Kranke P, Winner J, et al. Real-world use of the sufentanil sublingual tablet system for patient-controlled management of acute postoperative pain: a prospective noninterventional study. Curr Med Res Opin. 2020;36(2):277\u201384. https:\/\/doi.org\/10.1080\/03007995.2019.1681133.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"1320_CR35","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.athoracsur.2021.06.063","volume":"113","author":"I Lomangino","year":"2022","unstructured":"Lomangino I, Berni A, Lloret Madrid A, et al. Sublingual sufentanil in pain management after pulmonary resection: a randomized prospective study. Ann Thorac Surg. 2022;113(6):1867\u201372. https:\/\/doi.org\/10.1016\/j.athoracsur.2021.06.063.","journal-title":"Ann Thorac Surg"},{"issue":"12","key":"1320_CR36","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1177\/1060028019863144","volume":"53","author":"CE Reardon","year":"2019","unstructured":"Reardon CE, Kane-Gill SL, Smithburger PL, Dasta JF. Sufentanil sublingual tablet: a new option for acute pain management. Ann Pharmacother. 2019;53(12):1220\u20136. https:\/\/doi.org\/10.1177\/1060028019863144.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"1320_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2217\/pmt-2018-0090","volume":"9","author":"JR Miner","year":"2019","unstructured":"Miner JR, Melson TI, Leiman D, et al. Pooled phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. Pain Manag. 2019;9(3):259\u201371. https:\/\/doi.org\/10.2217\/pmt-2018-0090.","journal-title":"Pain Manag"},{"issue":"11","key":"1320_CR38","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.7150\/ijms.34656","volume":"16","author":"SK Oh","year":"2019","unstructured":"Oh SK, Lee IO, Lim BG, et al. Comparison of the analgesic effect of sufentanil versus fentanyl in intravenous patient-controlled analgesia after total laparoscopic hysterectomy: a randomized, double-blind, prospective study. Int J Med Sci. 2019;16(11):1439\u201346. https:\/\/doi.org\/10.7150\/ijms.34656.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1320_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1213\/ANE.0000000000007384","volume":"141","author":"FX Guyette","year":"2025","unstructured":"Guyette FX, Chaudhary P, Vincent LE, et al. A randomized controlled trial of sublingual sufentanil in early management of pain in trauma. Anesth Analg. 2025;141(1):172\u201380. https:\/\/doi.org\/10.1213\/ANE.0000000000007384.","journal-title":"Anesth Analg"},{"issue":"4 Suppl","key":"1320_CR40","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00002508-200207001-00002","volume":"18","author":"CE Inturrisi","year":"2002","unstructured":"Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain. 2002;18(4 Suppl):S3-13. https:\/\/doi.org\/10.1097\/00002508-200207001-00002.","journal-title":"Clin J Pain"},{"issue":"17","key":"1320_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174302","volume":"20","author":"J Listos","year":"2019","unstructured":"Listos J, \u0141upina M, Talarek S, Mazur A, Orzelska-G\u00f3rka J, Kotli\u0144ska J. The mechanisms involved in morphine addiction: an overview. Int J Mol Sci. 2019;20(17):4302. https:\/\/doi.org\/10.3390\/ijms20174302.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1320_CR42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/open.201900115","volume":"8","author":"K Maz\u00e1k","year":"2019","unstructured":"Maz\u00e1k K, Nosz\u00e1l B, Hosztafi S. Advances in the physicochemical profiling of opioid compounds of therapeutic interest. ChemistryOpen. 2019;8(7):879\u201387. https:\/\/doi.org\/10.1002\/open.201900115.","journal-title":"ChemistryOpen"},{"issue":"2","key":"1320_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1023\/a:1015932610010","volume":"6","author":"SD Roy","year":"1989","unstructured":"Roy SD, Flynn GL. Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil. Pharm Res. 1989;6(2):147\u201351. https:\/\/doi.org\/10.1023\/a:1015932610010.","journal-title":"Pharm Res"},{"issue":"1","key":"1320_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/0742-969x.1993.11882756","volume":"9","author":"T Davis","year":"1993","unstructured":"Davis T, Miser AW, Loprinzi CL, et al. Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. Hosp J. 1993;9(1):85\u201390. https:\/\/doi.org\/10.1080\/0742-969x.1993.11882756.","journal-title":"Hosp J"},{"issue":"1","key":"1320_CR45","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1097\/NCC.0000000000000784","volume":"44","author":"BW Dyal","year":"2021","unstructured":"Dyal BW, Powell-Roach KL, Robison J, Campbell B, Yoon SL, Wilkie DJ. Sublingual versus swallowed morphine: a comparison. Cancer Nurs. 2021;44(1):E13\u201322. https:\/\/doi.org\/10.1097\/NCC.0000000000000784.","journal-title":"Cancer Nurs"},{"key":"1320_CR46","unstructured":"Hydromorphone: Uses, Interactions, Mechanism of Action | DrugBank. https:\/\/go.drugbank.com\/drugs\/DB00327. Accessed 17 May 2026."},{"issue":"7","key":"1320_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/pme.12464","volume":"15","author":"MG Kestenbaum","year":"2014","unstructured":"Kestenbaum MG, Vilches AO, Messersmith S, et al. Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Med. 2014;15(7):1129\u201353. https:\/\/doi.org\/10.1111\/pme.12464.","journal-title":"Pain Med"},{"issue":"2","key":"1320_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s005200000183","volume":"9","author":"N Sarhill","year":"2001","unstructured":"Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001;9(2):84\u201396. https:\/\/doi.org\/10.1007\/s005200000183.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1320_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.33549\/physiolres.935354","volume":"74","author":"L Liu","year":"2025","unstructured":"Liu L, Xu M, Wang J, Hu Y, Huang Z. Research progress of hydromorphone in clinical application. Physiol Res. 2025;74(1):41\u20138. https:\/\/doi.org\/10.33549\/physiolres.935354.","journal-title":"Physiol Res"},{"key":"1320_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2016.06.025","volume":"65","author":"J Haumann","year":"2016","unstructured":"Haumann J, Geurts JW, van Kuijk SMJ, Kremer B, Joosten EA, van den Beuken-van Everdingen MHJ. Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. Eur J Cancer. 2016;65:121\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.025.","journal-title":"Eur J Cancer"},{"issue":"10","key":"1320_CR51","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00018-019-03047-y","volume":"76","author":"M Deng","year":"2019","unstructured":"Deng M, Chen SR, Pan HL. Presynaptic NMDA receptors control nociceptive transmission at the spinal cord level in neuropathic pain. Cell Mol Life Sci. 2019;76(10):1889\u201399. https:\/\/doi.org\/10.1007\/s00018-019-03047-y.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"1320_CR52","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1399-6576.2008.01597.x","volume":"52","author":"OMS Fredheim","year":"2008","unstructured":"Fredheim OMS, Moksnes K, Borchgrevink PC, Kaasa S, Dale O. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008;52(7):879\u201389. https:\/\/doi.org\/10.1111\/j.1399-6576.2008.01597.x.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"4","key":"1320_CR53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jpainsymman.2004.06.012","volume":"29","author":"RA Cruciani","year":"2005","unstructured":"Cruciani RA, Sekine R, Homel P, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manag. 2005;29(4):385\u201391. https:\/\/doi.org\/10.1016\/j.jpainsymman.2004.06.012.","journal-title":"J Pain Symptom Manag"},{"issue":"1-3","key":"1320_CR54","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.drugalcdep.2008.06.018","volume":"99","author":"F Fonseca","year":"2009","unstructured":"Fonseca F, Marti-Almor J, Pastor A, et al. Prevalence of long QTc interval in methadone maintenance patients. Drug Alcohol Depend. 2009;99(1\u20133):327\u201332. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.06.018.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1320_CR55","doi-asserted-by":"publisher","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","volume":"150","author":"MJ Krantz","year":"2009","unstructured":"Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MCP. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150(6):387\u201395. https:\/\/doi.org\/10.7326\/0003-4819-150-6-200903170-00103.","journal-title":"Ann Intern Med"},{"issue":"7","key":"1320_CR56","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0269216310375999","volume":"24","author":"NA Hagen","year":"2010","unstructured":"Hagen NA, Moulin DE, Brasher PM, et al. A formal feasibility study of sublingual methadone for breakthrough cancer pain. Palliat Med. 2010;24(7):696\u2013706. https:\/\/doi.org\/10.1177\/0269216310375999.","journal-title":"Palliat Med"},{"issue":"11","key":"1320_CR57","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1089\/jpm.2013.0522","volume":"17","author":"D Spaner","year":"2014","unstructured":"Spaner D. Effectiveness of the buccal mucosa route for methadone administration at the end of life. J Palliat Med. 2014;17(11):1262\u20135. https:\/\/doi.org\/10.1089\/jpm.2013.0522.","journal-title":"J Palliat Med"},{"issue":"1","key":"1320_CR58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5055\/jom.2010.0007","volume":"6","author":"A Gupta","year":"2010","unstructured":"Gupta A, Duckles B, Giordano J. Use of sublingual methadone for treating pain of chemotherapy-induced oral mucositis. J Opioid Manag. 2010;6(1):67\u20139. https:\/\/doi.org\/10.5055\/jom.2010.0007.","journal-title":"J Opioid Manag"},{"issue":"9","key":"1320_CR59","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","volume":"55","author":"MA Peltoniemi","year":"2016","unstructured":"Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059\u201377. https:\/\/doi.org\/10.1007\/s40262-016-0383-6.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1320_CR60","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/00000542-199704000-00021","volume":"86","author":"BA Orser","year":"1997","unstructured":"Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997;86(4):903\u201317. https:\/\/doi.org\/10.1097\/00000542-199704000-00021.","journal-title":"Anesthesiology"},{"key":"1320_CR61","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/978-3-540-74806-9_15","volume":"182","author":"B Sinner","year":"2008","unstructured":"Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;182:313\u201333. https:\/\/doi.org\/10.1007\/978-3-540-74806-9_15.","journal-title":"Handb Exp Pharmacol"},{"issue":"6","key":"1320_CR62","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bcp.12264","volume":"77","author":"P Rolan","year":"2014","unstructured":"Rolan P, Lim S, Sunderland V, Liu Y, Molnar V. The absolute bioavailability of racemic ketamine from a novel sublingual formulation. Br J Clin Pharmacol. 2014;77(6):1011\u20136. https:\/\/doi.org\/10.1111\/bcp.12264.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1320_CR63","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/clpt.2011.140","volume":"90","author":"MA Peltoniemi","year":"2011","unstructured":"Peltoniemi MA, Saari TI, Hagelberg NM, et al. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther. 2011;90(2):296\u2013302. https:\/\/doi.org\/10.1038\/clpt.2011.140.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1320_CR64","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/ALN.0b013e318218a881","volume":"114","author":"I Noppers","year":"2011","unstructured":"Noppers I, Olofsen E, Niesters M, et al. Effect of rifampicin on S-ketamine and S-norketamine plasma concentrations in healthy volunteers after intravenous S-ketamine administration. Anesthesiology. 2011;114(6):1435\u201345. https:\/\/doi.org\/10.1097\/ALN.0b013e318218a881.","journal-title":"Anesthesiology"},{"issue":"9","key":"1320_CR65","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/imj.15404","volume":"52","author":"B Maudlin","year":"2022","unstructured":"Maudlin B, Gibson SB, Aggarwal A. Long-term safety and efficacy of sublingual ketamine troches\/lozenges in chronic non-malignant pain management. Intern Med J. 2022;52(9):1538\u201343. https:\/\/doi.org\/10.1111\/imj.15404.","journal-title":"Intern Med J"},{"issue":"10","key":"1320_CR66","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/09638288.2023.2218652","volume":"46","author":"D Johnson","year":"2024","unstructured":"Johnson D, Feng L, Johnson C. Retrospective review of the efficacy for sublingual ketamine in the treatment of chronic low back pain defined by a cause and central functional pain symptom focused clinical model. Disabil Rehabil. 2024;46(10):2117\u201324. https:\/\/doi.org\/10.1080\/09638288.2023.2218652.","journal-title":"Disabil Rehabil"},{"issue":"2","key":"1320_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/15360288.2016.1161690","volume":"30","author":"O Zekry","year":"2016","unstructured":"Zekry O, Gibson SB, Aggarwal A. Subanesthetic, subcutaneous ketamine infusion therapy in the treatment of chronic nonmalignant pain. J Pain Palliat Care Pharmacother. 2016;30(2):91\u20138. https:\/\/doi.org\/10.3109\/15360288.2016.1161690.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"4","key":"1320_CR68","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/15360288.2025.2531008","volume":"39","author":"YC Lee","year":"2025","unstructured":"Lee YC, Zhao E, Lee KKH, et al. Sublingual ketamine as breakthrough analgesia in patients with advanced cancer-a feasibility randomised controlled repeated cross-over trial. J Pain Palliat Care Pharmacother. 2025;39(4):454\u201367. https:\/\/doi.org\/10.1080\/15360288.2025.2531008.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"9","key":"1320_CR69","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s40261-021-01066-x","volume":"41","author":"CC Chong","year":"2021","unstructured":"Chong CC, Schug SA. Efficacy and tolerability of oral compared with sublingual ketamine lozenges as rescue analgesics in adults for acute pain: the OSKet trial. Clin Drug Investig. 2021;41(9):817\u201323. https:\/\/doi.org\/10.1007\/s40261-021-01066-x.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"1320_CR70","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","volume":"178","author":"A Feder","year":"2021","unstructured":"Feder A, Costi S, Rutter SB, et al. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry. 2021;178(2):193\u2013202. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20050596.","journal-title":"Am J Psychiatry"},{"key":"1320_CR71","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2023.04.141","volume":"335","author":"TM Hietamies","year":"2023","unstructured":"Hietamies TM, McInnes LA, Klise AJ, et al. The effects of ketamine on symptoms of depression and anxiety in real-world care settings: a retrospective controlled analysis. J Affect Disord. 2023;335:484\u201392. https:\/\/doi.org\/10.1016\/j.jad.2023.04.141.","journal-title":"J Affect Disord"},{"issue":"12","key":"1320_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012033.pub4","volume":"12","author":"EC Brinck","year":"2018","unstructured":"Brinck EC, Tiippana E, Heesen M, et al. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database Syst Rev. 2018;12(12):CD012033. https:\/\/doi.org\/10.1002\/14651858.CD012033.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"1320_CR73","unstructured":"Ketamine: A Review of an Established Yet Often Underappreciated Medication. Anesthesia Patient Safety Foundation. https:\/\/www.apsf.org\/article\/ketamine-a-review-of-an-established-yet-often-underappreciated-medication\/. Accessed 17 May 2026."},{"issue":"5","key":"1320_CR74","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/AAP.0000000000000806","volume":"43","author":"ES Schwenk","year":"2018","unstructured":"Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456\u201366. https:\/\/doi.org\/10.1097\/AAP.0000000000000806.","journal-title":"Reg Anesth Pain Med"},{"issue":"2","key":"1320_CR75","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/SPC.0b013e328352812c","volume":"6","author":"RF Bell","year":"2012","unstructured":"Bell RF. Ketamine for chronic noncancer pain: concerns regarding toxicity. Curr Opin Support Palliat Care. 2012;6(2):183\u20137. https:\/\/doi.org\/10.1097\/SPC.0b013e328352812c.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"6","key":"1320_CR76","doi-asserted-by":"publisher","first-page":"E755","DOI":"10.36076\/ppj.20.5.E755","volume":"20","author":"J Aviram","year":"2017","unstructured":"Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755\u201396.","journal-title":"Pain Physician"},{"issue":"8","key":"1320_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084204","volume":"25","author":"NM Blebea","year":"2024","unstructured":"Blebea NM, Pricopie AI, Vlad RA, Hancu G. Phytocannabinoids: exploring pharmacological profiles and their impact on therapeutical use. Int J Mol Sci. 2024;25(8):4204. https:\/\/doi.org\/10.3390\/ijms25084204.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1320_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063344","volume":"23","author":"C Pagano","year":"2022","unstructured":"Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: therapeutic use in clinical practice. Int J Mol Sci. 2022;23(6):3344. https:\/\/doi.org\/10.3390\/ijms23063344.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1320_CR79","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.3390\/molecules28165980","volume":"28","author":"N Martinez Naya","year":"2023","unstructured":"Martinez Naya N, Kelly J, Corna G, Golino M, Abbate A, Toldo S. Molecular and cellular mechanisms of action of cannabidiol. Molecules. 2023;28(16):5980. https:\/\/doi.org\/10.3390\/molecules28165980.","journal-title":"Molecules"},{"issue":"3","key":"1320_CR80","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737\u201353. https:\/\/doi.org\/10.1111\/bph.12944.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"1320_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28073271","volume":"28","author":"J Castillo-Arellano","year":"2023","unstructured":"Castillo-Arellano J, Canseco-Alba A, Cutler SJ, Le\u00f3n F. The polypharmacological effects of cannabidiol. Molecules. 2023;28(7):3271. https:\/\/doi.org\/10.3390\/molecules28073271.","journal-title":"Molecules"},{"issue":"22","key":"1320_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228870","volume":"21","author":"J Mlost","year":"2020","unstructured":"Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 2020;21(22):8870. https:\/\/doi.org\/10.3390\/ijms21228870.","journal-title":"Int J Mol Sci"},{"key":"1320_CR83","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","volume":"80","author":"AC Howlett","year":"2017","unstructured":"Howlett AC, Abood ME. CB1 and CB2 receptor pharmacology. Adv Pharmacol. 2017;80:169\u2013206. https:\/\/doi.org\/10.1016\/bs.apha.2017.03.007.","journal-title":"Adv Pharmacol"},{"key":"1320_CR84","unstructured":"Mamballn A. The cannabinoids mechanism of action: an overview. 2023;6(Suppl. 2):109-113."},{"issue":"4","key":"1320_CR85","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.01.008","volume":"180","author":"T Hua","year":"2020","unstructured":"Hua T, Li X, Wu L, et al. Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures. Cell. 2020;180(4):655-665.e18. https:\/\/doi.org\/10.1016\/j.cell.2020.01.008.","journal-title":"Cell"},{"issue":"4","key":"1320_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11040660","volume":"11","author":"DM Kopustinskiene","year":"2022","unstructured":"Kopustinskiene DM, Masteikova R, Lazauskas R, Bernatoniene J. Cannabis sativa L. bioactive compounds and their protective role in oxidative stress and inflammation. Antioxidants (Basel). 2022;11(4):660. https:\/\/doi.org\/10.3390\/antiox11040660.","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"1320_CR87","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199\u2013215. https:\/\/doi.org\/10.1038\/sj.bjp.0707442.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"1320_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.682","volume":"8","author":"DL de Almeida","year":"2020","unstructured":"de Almeida DL, Devi LA. Diversity of molecular targets and signaling pathways for CBD. Pharmacol Res Perspect. 2020;8(6):e00682. https:\/\/doi.org\/10.1002\/prp2.682.","journal-title":"Pharmacol Res Perspect"},{"issue":"20","key":"1320_CR89","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790\u2013805. https:\/\/doi.org\/10.1111\/bph.13250.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1320_CR90","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/bcp.14617","volume":"87","author":"A Hosseini","year":"2021","unstructured":"Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Br J Clin Pharmacol. 2021;87(4):2070\u20137. https:\/\/doi.org\/10.1111\/bcp.14617.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1320_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020236","volume":"17","author":"M Lacerda","year":"2025","unstructured":"Lacerda M, Carona A, Castanheira S, Falc\u00e3o A, Bicker J, Fortuna A. Pharmacokinetics of non-psychotropic phytocannabinoids. Pharmaceutics. 2025;17(2):236. https:\/\/doi.org\/10.3390\/pharmaceutics17020236.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1320_CR92","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11095-023-03469-1","volume":"40","author":"GTY Yau","year":"2023","unstructured":"Yau GTY, Tai W, Arnold JC, Chan HK, Kwok PCL. Cannabidiol for the treatment of brain disorders: therapeutic potential and routes of administration. Pharm Res. 2023;40(5):1087\u2013114. https:\/\/doi.org\/10.1007\/s11095-023-03469-1.","journal-title":"Pharm Res"},{"issue":"2","key":"1320_CR93","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1089\/can.2023.0229","volume":"10","author":"S Tarlovski","year":"2025","unstructured":"Tarlovski S, Bar Kadmon A, Goldberg E, Segal D, Gavish D, Stepensky D. Comparative pharmacokinetic assessment of innovative sublingual, rectal and vaporizer cannabis products versus approved cannabis products in healthy volunteers. Cannabis Cannabinoid Res. 2025;10(2):e289\u201398. https:\/\/doi.org\/10.1089\/can.2023.0229.","journal-title":"Cannabis Cannabinoid Res."},{"issue":"5","key":"1320_CR94","doi-asserted-by":"publisher","first-page":"e1423","DOI":"10.1089\/can.2023.0117","volume":"9","author":"DA Johnson","year":"2024","unstructured":"Johnson DA, Funnell MP, Heaney LM, et al. Cannabidiol oil ingested as sublingual drops or within gelatin capsules shows similar pharmacokinetic profiles in healthy males. Cannabis Cannabinoid Res. 2024;9(5):e1423\u201332. https:\/\/doi.org\/10.1089\/can.2023.0117.","journal-title":"Cannabis Cannabinoid Res."},{"issue":"2","key":"1320_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020244","volume":"17","author":"SE O\u2019Sullivan","year":"2024","unstructured":"O\u2019Sullivan SE, Jensen SS, Kolli AR, Nikolajsen GN, Bruun HZ, Hoeng J. Strategies to improve cannabidiol bioavailability and drug delivery. Pharmaceuticals (Basel). 2024;17(2):244. https:\/\/doi.org\/10.3390\/ph17020244.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1320_CR96","unstructured":"PRIME PubMed | Pharmacokinetics of Sativex\u00ae in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. https:\/\/www.unboundmedicine.com\/medline\/citation\/32054131\/Pharmacokinetics_of_Sativex\u00ae_in_Dogs:_Towards_a_Potential_Cannabinoid_Based_Therapy_for_Canine_Disorders_. Accessed 17 May 2026."},{"issue":"2","key":"1320_CR97","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jps.20766","volume":"96","author":"J Mannila","year":"2007","unstructured":"Mannila J, J\u00e4rvinen T, J\u00e4rvinen K, Jarho P. Precipitation complexation method produces cannabidiol\/beta-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. J Pharm Sci. 2007;96(2):312\u20139. https:\/\/doi.org\/10.1002\/jps.20766.","journal-title":"J Pharm Sci"},{"issue":"1","key":"1320_CR98","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejps.2005.04.020","volume":"26","author":"J Mannila","year":"2005","unstructured":"Mannila J, J\u00e4rvinen T, J\u00e4rvinen K, Tarvainen M, Jarho P. Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. Eur J Pharm Sci. 2005;26(1):71\u20137. https:\/\/doi.org\/10.1016\/j.ejps.2005.04.020.","journal-title":"Eur J Pharm Sci"},{"issue":"17","key":"1320_CR99","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.lfs.2005.08.025","volume":"78","author":"J Mannila","year":"2006","unstructured":"Mannila J, J\u00e4rvinen T, J\u00e4rvinen K, Tervonen J, Jarho P. Sublingual administration of Delta9-tetrahydrocannabinol\/beta-cyclodextrin complex increases the bioavailability of Delta9-tetrahydrocannabinol in rabbits. Life Sci. 2006;78(17):1911\u20134. https:\/\/doi.org\/10.1016\/j.lfs.2005.08.025.","journal-title":"Life Sci"},{"issue":"8","key":"1320_CR100","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.7326\/M21-4520","volume":"175","author":"MS McDonagh","year":"2022","unstructured":"McDonagh MS, Morasco BJ, Wagner J, et al. Cannabis-based products for chronic pain\u202f: a systematic review. Ann Intern Med. 2022;175(8):1143\u201353. https:\/\/doi.org\/10.7326\/M21-4520.","journal-title":"Ann Intern Med"},{"issue":"3","key":"1320_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13030530","volume":"13","author":"BW Johnson","year":"2025","unstructured":"Johnson BW, Strand NH, Raynak JC, et al. Cannabinoids in chronic pain management: a review of the history, efficacy, applications, and risks. Biomedicines. 2025;13(3):530. https:\/\/doi.org\/10.3390\/biomedicines13030530.","journal-title":"Biomedicines"},{"issue":"12","key":"1320_CR102","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcph.1961","volume":"61","author":"M Kawka","year":"2021","unstructured":"Kawka M, Erridge S, Holvey C, et al. Clinical outcome data of first cohort of chronic pain patients treated with cannabis\u2010based sublingual oils in the United Kingdom: analysis from the UK Medical Cannabis Registry. J Clin Pharmacol. 2021;61(12):1545\u201354. https:\/\/doi.org\/10.1002\/jcph.1961.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1320_CR103","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14737175.2023.2195551","volume":"23","author":"J Tait","year":"2023","unstructured":"Tait J, Erridge S, Holvey C, et al. Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry. Expert Rev Neurother. 2023;23(4):413\u201323. https:\/\/doi.org\/10.1080\/14737175.2023.2195551.","journal-title":"Expert Rev Neurother"},{"key":"1320_CR104","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/JPR.S240011","volume":"13","author":"MA \u00dcberall","year":"2020","unstructured":"\u00dcberall MA. A review of scientific evidence for THC:CBD oromucosal spray (Nabiximols) in the management of chronic pain. J Pain Res. 2020;13:399\u2013410. https:\/\/doi.org\/10.2147\/JPR.S240011.","journal-title":"J Pain Res"},{"key":"1320_CR105","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2147\/JPR.S192174","volume":"12","author":"MA Ueberall","year":"2019","unstructured":"Ueberall MA, Essner U, Mueller-Schwefe GH. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res. 2019;12:1577\u2013604. https:\/\/doi.org\/10.2147\/JPR.S192174.","journal-title":"J Pain Res"},{"issue":"5","key":"1320_CR106","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jpain.2012.01.003","volume":"13","author":"RK Portenoy","year":"2012","unstructured":"Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438\u201349. https:\/\/doi.org\/10.1016\/j.jpain.2012.01.003.","journal-title":"J Pain"},{"issue":"2","key":"1320_CR107","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","volume":"55","author":"AH Lichtman","year":"2018","unstructured":"Lichtman AH, Lux EA, McQuade R, et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manag. 2018;55(2):179-188.e1. https:\/\/doi.org\/10.1016\/j.jpainsymman.2017.09.001.","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"1320_CR108","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10485","volume":"13","author":"D Robinson","year":"2022","unstructured":"Robinson D, Ritter S, Yassin M. Comparing sublingual and inhaled cannabis therapies for low back pain: an observational open-label study. Rambam Maimonides Med J. 2022;13(4):e0026. https:\/\/doi.org\/10.5041\/RMMJ.10485.","journal-title":"Rambam Maimonides Med J"},{"issue":"7","key":"1320_CR109","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s11916-024-01252-4","volume":"28","author":"MO Botea","year":"2024","unstructured":"Botea MO, Andereggen L, Urman RD, Luedi MM, Romero CS. Cannabinoids for acute pain management: approaches and rationale. Curr Pain Headache Rep. 2024;28(7):681\u20139. https:\/\/doi.org\/10.1007\/s11916-024-01252-4.","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"1320_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.4790","volume":"29","author":"VH Gonz\u00e1lez C\u00e1rdenas","year":"2025","unstructured":"Gonz\u00e1lez C\u00e1rdenas VH, Valdivieso D\u00edaz M, Mateus Almeciga CF, et al. Cannabinoids for acute postoperative pain management: a systematic review and meta-analysis of clinical trials. Eur J Pain. 2025;29(3):e4790. https:\/\/doi.org\/10.1002\/ejp.4790.","journal-title":"Eur J Pain"},{"issue":"3","key":"1320_CR111","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/aas.12851","volume":"61","author":"AJ Stevens","year":"2017","unstructured":"Stevens AJ, Higgins MD. A systematic review of the analgesic efficacy of cannabinoid medications in the management of acute pain. Acta Anaesthesiol Scand. 2017;61(3):268\u201380. https:\/\/doi.org\/10.1111\/aas.12851.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"7","key":"1320_CR112","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/rapm-2020-101340","volume":"45","author":"FW Abdallah","year":"2020","unstructured":"Abdallah FW, Hussain N, Weaver T, Brull R. Analgesic efficacy of cannabinoids for acute pain management after surgery: a systematic review and meta-analysis. Reg Anesth Pain Med. 2020;45(7):509\u201319. https:\/\/doi.org\/10.1136\/rapm-2020-101340.","journal-title":"Reg Anesth Pain Med"},{"key":"1320_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-025-03606-w","volume":"26","author":"Y Sun","year":"2026","unstructured":"Sun Y, Yao Y, Li Y, Deng W. Dexmedetomidine for opioid-sparing postoperative analgesia: a systematic review and meta-analysis. BMC Anesthesiol. 2026;26:103. https:\/\/doi.org\/10.1186\/s12871-025-03606-w.","journal-title":"BMC Anesthesiol"},{"issue":"2","key":"1320_CR114","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-020-00926-z","volume":"25","author":"S Rao","year":"2021","unstructured":"Rao S, Rajan N. Dexmedetomidine as an adjunct for regional anesthetic nerve blocks. Curr Pain Headache Rep. 2021;25(2):8. https:\/\/doi.org\/10.1007\/s11916-020-00926-z.","journal-title":"Curr Pain Headache Rep"},{"issue":"4","key":"1320_CR115","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/bcpt.13979","volume":"134","author":"S Amna","year":"2024","unstructured":"Amna S, \u00d8hlenschlaeger T, Saedder EA, Sigaard JV, Bergmann TK. Review of clinical pharmacokinetics and pharmacodynamics of clonidine as an adjunct to opioids in palliative care. Basic Clin Pharmacol Toxicol. 2024;134(4):485\u201397. https:\/\/doi.org\/10.1111\/bcpt.13979.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"1320_CR116","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/s0952-8180(05)80018-2","volume":"6","author":"FE Cunningham","year":"1994","unstructured":"Cunningham FE, Baughman VL, Peters J, Laurito CE. Comparative pharmacokinetics of oral versus sublingual clonidine. J Clin Anesth. 1994;6(5):430\u20133. https:\/\/doi.org\/10.1016\/s0952-8180(05)80018-2.","journal-title":"J Clin Anesth"},{"key":"1320_CR117","unstructured":"U.S. Food and Drug Administration. IGALMI (dexmedetomidine) sublingual film [prescribing information]. Published online April 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215390s000lbl.pdf. Accessed 18 Jan 2026."},{"issue":"4","key":"1320_CR118","doi-asserted-by":"publisher","first-page":"P46","DOI":"10.1016\/j.jpain.2011.02.185","volume":"12","author":"L Webster","year":"2011","unstructured":"Webster L, Freyer A, Rodzvilla J, Mack R, Reeves R. An evaluation of the impact of opioid use on the analgesic effects of REC1100 in chronic low back patients. J Pain. 2011;12(4):P46. https:\/\/doi.org\/10.1016\/j.jpain.2011.02.185.","journal-title":"J Pain"},{"issue":"8","key":"1320_CR119","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jama.2022.0799","volume":"327","author":"SH Preskorn","year":"2022","unstructured":"Preskorn SH, Zeller S, Citrome L, et al. Effect of sublingual dexmedetomidine vs placebo on acute agitation associated with bipolar disorder: a randomized clinical trial. JAMA. 2022;327(8):727\u201336. https:\/\/doi.org\/10.1001\/jama.2022.0799.","journal-title":"JAMA"},{"issue":"8","key":"1320_CR120","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40262-017-0507-7","volume":"56","author":"MAS Weerink","year":"2017","unstructured":"Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893\u2013913. https:\/\/doi.org\/10.1007\/s40262-017-0507-7.","journal-title":"Clin Pharmacokinet"},{"key":"1320_CR121","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaf335","author":"Z Coralic","year":"2025","unstructured":"Coralic Z, Allai M, Hwang C, Michaels B, Takamoto P. Severe hypotension following sublingual dexmedetomidine administration in an elderly patient. Am J Health Syst Pharm. 2025. https:\/\/doi.org\/10.1093\/ajhp\/zxaf335.","journal-title":"Am J Health Syst Pharm"},{"issue":"3A","key":"1320_CR122","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/s0002-9343(97)00203-9","volume":"104","author":"JR Vane","year":"1998","unstructured":"Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(3A):2S-8S. https:\/\/doi.org\/10.1016\/s0002-9343(97)00203-9. (discussion 21S-22S).","journal-title":"Am J Med"},{"issue":"Suppl 5","key":"1320_CR123","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2165\/00003495-199600525-00004","volume":"52","author":"JN Cashman","year":"1996","unstructured":"Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996;52(Suppl 5):13\u201323. https:\/\/doi.org\/10.2165\/00003495-199600525-00004.","journal-title":"Drugs"},{"issue":"2","key":"1320_CR124","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpain.2015.12.008","volume":"17","author":"R Chou","year":"2016","unstructured":"Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists\u2019 Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131\u201357. https:\/\/doi.org\/10.1016\/j.jpain.2015.12.008.","journal-title":"J Pain"},{"key":"1320_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01328","volume":"10","author":"S Hua","year":"2019","unstructured":"Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Front Pharmacol. 2019;10:1328. https:\/\/doi.org\/10.3389\/fphar.2019.01328.","journal-title":"Front Pharmacol"},{"key":"1320_CR126","unstructured":"DailyMed - KETOROLAC TROMETHAMINE tablet, film coated. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=688f5dec-a6db-43c6-a1f8-5df99d08d395. Accessed 21 May 2026."},{"issue":"9","key":"1320_CR127","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.clinthera.2008.09.011","volume":"30","author":"JF Gal\u00e1n-Herrera","year":"2008","unstructured":"Gal\u00e1n-Herrera JF, Poo JL, Maya-Barrios JA, et al. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Clin Ther. 2008;30(9):1667\u201374. https:\/\/doi.org\/10.1016\/j.clinthera.2008.09.011.","journal-title":"Clin Ther"},{"issue":"3","key":"1320_CR128","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijom.2010.10.026","volume":"40","author":"PaK Trindade","year":"2011","unstructured":"Trindade PaK, Giglio FPM, Colombini-Ishikiriama BL, et al. Comparison of oral versus sublingual piroxicam during postoperative pain management after lower third molar extraction. Int J Oral Maxillofac Surg. 2011;40(3):292\u20137. https:\/\/doi.org\/10.1016\/j.ijom.2010.10.026.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"1","key":"1320_CR129","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tripleo.2011.05.027","volume":"114","author":"PAK Trindade","year":"2012","unstructured":"Trindade PAK, Giglio FPM, Colombini-Ishikiriama BL, et al. Sublingual ketorolac and sublingual piroxicam are equally effective for postoperative pain, trismus, and swelling management in lower third molar removal. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(1):27\u201334. https:\/\/doi.org\/10.1016\/j.tripleo.2011.05.027.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"1","key":"1320_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s13005-024-00453-x","volume":"20","author":"AF Mohamed","year":"2024","unstructured":"Mohamed AF, El-Asfouri HA, Amin SAW. Effect of sublingual fast-dissolving piroxicam premedication on postoperative pain experience in mandibular molars with non-vital pulp: a randomized double-blind controlled trial. Head Face Med. 2024;20(1):52. https:\/\/doi.org\/10.1186\/s13005-024-00453-x.","journal-title":"Head Face Med"},{"issue":"1","key":"1320_CR131","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000102918","volume":"79","author":"B Altay","year":"2007","unstructured":"Altay B, Horasanli K, Sarica K, Tanriverdi O, Kendirci M, Miroglu C. Double-blind, placebo-controlled, randomized clinical trial of sublingual or intramuscular piroxicam in the treatment of renal colic. A comparative study. Urol Int. 2007;79(1):73\u20135. https:\/\/doi.org\/10.1159\/000102918.","journal-title":"Urol Int"},{"issue":"1","key":"1320_CR132","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1464-410x.1998.00505.x","volume":"81","author":"A Superv\u00eda","year":"1998","unstructured":"Superv\u00eda A, Pedro-Botet J, Nogu\u00e9s X, et al. Piroxicam fast-dissolving dosage form vs diclofenac sodium in the treatment of acute renal colic: a double-blind controlled trial. Br J Urol. 1998;81(1):27\u201330.","journal-title":"Br J Urol"},{"issue":"9","key":"1320_CR133","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/archdischild-2012-303527","volume":"98","author":"E Neri","year":"2013","unstructured":"Neri E, Maestro A, Minen F, et al. Sublingual ketorolac versus sublingual tramadol for moderate to severe post-traumatic bone pain in children: a double-blind, randomised, controlled trial. Arch Dis Child. 2013;98(9):721\u20134. https:\/\/doi.org\/10.1136\/archdischild-2012-303527.","journal-title":"Arch Dis Child"},{"key":"1320_CR134","unstructured":"Medication Guide for Non-Steroidal Anti-Inflammatory Drugs. FDA-approved medication guide. Published online 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020938s020,021530s008MedGuide.pdf"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01320-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01320-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01320-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:28:41Z","timestamp":1786948121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01320-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":134,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1320"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01320-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sarang S. Koushik, Karina Gritsenko, Dhanesh D. Binda, Isaac S. Daybell, Nathan S. Hill, Jagun Raghavan, Emmanuella Borukh, Bradford B. Smith, Molly Kraus, and Naum Shaparin declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sarang S. Koushik, Karina Gritsenko, Bradford B. Smith, Molly Kraus, and Naum Shaparin were responsible for conception and design and contributed to critical revision of the manuscript for important intellectual content. Dhanesh D. Binda, Isaac S. Daybell, Nathan S. Hill, Jagun Raghavan, and Emmanuella Borukh were responsible for literature review, data synthesis, and drafting the manuscript. All authors have read and approved the final version of the manuscript.","order":2,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}